Genfit SA - GNFTF stock

From OTC Wiki



Genfit S.A. is a biopharmaceutical company based in Loos, France, specializing in the discovery and development of drug candidates and diagnostic solutions for metabolic and liver-related diseases; its key developments include Elafibranor in Phase III clinical trial for primary biliary cholangitis, NIS4 technology for diagnosing nonalcoholic steatohepatitis (NASH) and fibrosis, as well as various drug candidates for Urea Cycle Disorder (UCD), Organic Acidemia Disorder (OAD), cholangiocarcinoma (CCA), acute-on-chronic liver failure, and hyperammonemia stabilization. The company also has licensing agreements for NASHnext and GNS561 with Labcorp and Genoscience Pharma, respectively.[1]


Genfit S.A. was founded in 1999 in Loos, France. The company originated as a biopharmaceutical firm with a focus on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases.[2]

Genfit's founding was driven by the growing need for innovative treatments for metabolic disorders and liver diseases, which pose significant health challenges worldwide. The company aimed to leverage its expertise in biopharmaceutical research and development to address these unmet medical needs. As Genfit evolved, it focused on the development of novel therapeutics and diagnostic technologies for various liver conditions, including nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), cholangiocarcinoma (CCA), and acute-on-chronic liver failure.[3]

One of the company's key drug candidates is Elafibranor, which reached Phase III clinical trials for the treatment of patients with primary biliary cholangitis, a chronic liver disease characterized by inflammation and destruction of the bile ducts. In addition to its drug development efforts, Genfit also worked on diagnostic solutions for liver diseases, such as NIS4 technology, designed to aid in the diagnosis of NASH and fibrosis, providing clinicians with a valuable tool for better patient management and treatment decisions. As Genfit S.A. continued to grow and expand its pipeline, the company forged strategic partnerships and licensing agreements with other healthcare companies to advance the development and commercialization of its products.[3]

  1. Yahoo Finance. GNFTF Stock Profile. Retrieved on 8/29/2023.
  2. Genfit. Retrieved on 8/29/2023.
  3. 3.0 3.1 About Genfit. Retrieved on 8/29/2023.

The page is authored by: Wisdom Tree